ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ネララビン

Nelarabine

HCID 3011155
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
121032-29-9
標準SMILES
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
InChIKey
IXOXBSCIXZEQEQ-UHTZMRCNSA-N
分子式
C11H15N5O5
平均分子量
297.27 g/mol
単同位体質量
297.1073186

概要

Nelarabine is a purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N9-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G). It has a role as an antineoplastic agent, a prodrug and a DNA synthesis inhibitor. It is a purine nucleoside, a beta-D-arabinoside and a monosaccharide derivative. It is functionally related to a guanine and a 9-beta-D-arabinofuranosylguanine.

名称と識別子

優先名称
Nelarabine
IUPAC
(2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
現地名
ネララビン
英語名
Nelarabine
分子式
C11H15N5O5
分子量
297.27

名称と別名

Nelarabine121032-29-9NelzarabineArranonAtriance506U78506UGW-506U78AttrianceNSC-686673GW506U782-Amino-6-methoxypurine arabinoside
名称をさらに表示
ネララビンネルザラビンネララビン (JAN)アラノンジー2-アミノ-6-メトキシプリンアラビノシド6-メトキシ-9-β-D-アラビノフラノシル-9H-プリン-2-アミン(2R)-2β-(2-アミノ-6-メトキシ-9H-プリン-9-イル)-5β-(ヒドロキシメチル)テトラヒドロフラン-3β,4α-ジオール(2R,3S,4S,5R)-2-(2-アミノ-6-メトキシ-9H-プリン-9-イル)-5-(ヒドロキシメチル)オキソラン-3,4-ジオール9-(β-D-アラビノフラノシル)-6-メトキシ-9H-プリン-2-アミンMAYNELARABINCS-1953GW 506U78Nelarabine D4
compound 506U78Nelarabina2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purineDTXSID6046842NSC-755985(2R,3S,4S,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diolCHEBI:63612NSC-759876

データベース識別子

CAS
121032-29-9

物性

構造計算による物性補完中

XLogP
-0.7
極性表面積
149 Ų
水素結合供与体数
4
水素結合受容体数
9
回転可能結合数
3
重原子数
21
形式電荷
0
複雑度
377

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LogP-1
Solubility · 2 件

Slightly soluble to soluble in water

1.39e+01 g/L

Human Drugs · 3 件

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point · 2 件

209-217 °C (with decomposition)

209 - 217 °C (decomposition)

Physical DescriptionSolid

物理化学的性質

融点
209 · 209-217°
比旋光度
20 · D20 +55.9° (c = 0.27 in DMF)
沸点
721 · 721.0±70.0 °C(Predicted)
比重(密度)
1.98 · 1.98±0.1 g/cm3(Predicted)
貯蔵温度
2 · 2-8°C(protect from light)
溶解性
DMSO(わずかに)、メタノール(わずかに、加熱)、水(わずかに、超音波処理)
外見

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H302 (16.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 6 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesMuta. 2 (66.7%)

毒性情報

Hepatotoxicity · 1 件

In clinical trials, serum enzymes elevations occurred in a small proportion of patients treated with nelarabine when given as sole therapy for refractory or relapsed acute leukemia. These elevations are generally mild-to-moderate, transient and asymptomatic. Elevations of aminotransferase levels above 5 times the upper limit of normal are reported in 4% of patients with leukemia receiving nelarabine. The elevations rarely require dose adjustment or delay in therapy. Cases of clinically apparent liver injury due to nelarabine have been reported to occur, but few details are available. A single case report of clinically apparent liver injury attributed to nelarabine has been published with rapid onset of jaundice during a second course of nelarabine, a hepatocellular pattern of enzyme elevations, no immunoallergic or autoimmune features and a rapid improvement upon stopping.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Nelarabine

vLess-DILI-concern

4

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

安全データ

化学と産業

薬理情報

ATC Code · 3 件

L01BB07

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingNelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro, and binding is independent of nelarabine or ara-G concentrations up to 600 µM.
Pharmacodynamics · 1 件

Nelarabine is a prodrug of the cytotoxic deoxyguanosine analogue 9-&szlig;-D-arabinofuranosylguanine (ara-G). Nelarabine is demethylated by adenosine deaminase (ADA) to ara-G. Ara-G is then transported into cells, where it undergoes three phosphorylation steps, resulting in the formation of ara-G triphosphate (ara-GTP). In the first phosphorylation step, ara-G is converted to ara-G monophosphate (ara-GMP). Ara-GMP is then monophosphorylated by deoxyguanosine kinase and deoxycytidine kinase to ara-G diphosphate, and then subsequently to the active ara-G triphosphate (ara-GTP). Ara-GTP is the one that exerts the pharmacological effect. Pre-clinical studies have demonstrated that targeted T-cells possess marked sensitivity to the agent. Since T lymphoblasts have a higher expression of deoxycytidine kinase, ara-G preferentially accumulates in T cells over B cells, thus showing higher toxicity to T lymphoblasts.[A2331,AA2334,A2335]

Mechanism of Action · 1 件

Once nelarabine is metabolized into ara-GTP, the metabolite accumulates in leukemic blasts and incorporates into DNA to exert its S phase-specific cytotoxic effects, leading to the induction of fragmentation and apoptosis. As a nucleoside analog, Ara-GTP competes with endogenous deoxyGTP (dGTP) for incorporation into DNA. Due to its intact 3'-OH group, ara-GTP can be incorporated into the growing DNA strand without absolute chain termination. Despite that, the inclusion of ara-GTP into DNA strand can impair proper DNA repair processes, although the exact mechanism is not well understood, leading to inhibition of DNA elongation, apoptosis, and cellular destruction. Additional cytotoxic activities may exist, but these are not fully understood.

Biological Half-Life · 1 件

Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients. For pediatric patients, the half-life of nelarabine and ara-G are 13 minutes and 2 hours, respectively. Because the intracellular levels of ara-GTP were so prolonged, its elimination half-life could not be accurately estimated.

関連反応

8 件
反応記録を作成
HRID 21504 の反応式
HRID 21504生成物として
HRID 21506 の反応式
HRID 21506反応物として
HRID 21507 の反応式
HRID 21507反応物として
HRID 399383 の反応式
HRID 399383反応物として
HRID 1288795 の反応式
HRID 1288795反応物として
HRID 1736055 の反応式
HRID 1736055生成物として
HRID 1736057 の反応式
HRID 1736057反応物として
HRID 2396448 の反応式
HRID 2396448反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
PubChem CID
3011155
DTXSID
DTXSID6046842
ChEMBL
CHEMBL1201112
ChEBI
CHEBI:63612
UNII
60158CV180
EC Number
642-916-9
Nikkaji
J679.698B
個体
酸解離定数(Pka)
13.07 · 13.07±0.70(Predicted)
色
白い
水溶解度
2 O: · H2O: 5mg/mL, clear (warmed)
InChI
InChI=1/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/s3
InChIKey
IXOXBSCIXZEQEQ-GCTRTDOSNA-N
SMILES
N1(C=NC2C(OC)=NC(N)=NC1=2)[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 |&1:12,13,15,17,r|
CAS データベース
121032 · 121032-29-9(CAS DataBase Reference)
wgk
WGK 3
ストレージクラス
11 - Combustible Solids
Metabolism/Metabolites · 1 件

The principal route of metabolism for nelarabine is O-demethylation by adenosine deaminase to form ara-G, which undergoes hydrolysis to form guanine. In addition, some nelarabine is hydrolyzed to form methylguanine, which is O-demethylated to form guanine. Guanine is N-deaminated to form xanthine, which is further oxidized to yield uric acid. Ring opening of uric acid followed by further oxidation results in the formation of allantoin. Ring opening of uric acid followed by further oxidation results in the formation of allantoin.

FDA Pharmacological Classification · 6 件

60158CV180

NELARABINE

Mechanisms of Action [MoA] - Nucleic Acid Synthesis Inhibitors

Established Pharmacologic Class [EPC] - Nucleoside Metabolic Inhibitor

Nelarabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of nelarabine is as a Nucleic Acid Synthesis Inhibitor.

NELARABINE

Absorption, Distribution and Excretion · 4 件

Following intravenous administration of nelarabine to adult patients with refractory leukemia or lymphoma, plasma ara-G Cmax values generally occurred at the end of the nelarabine infusion and were generally higher than nelarabine Cmax values, suggesting rapid and extensive conversion of nelarabine to ara-G. Mean plasma nelarabine and ara-G Cmax values were 5.0 ± 3.0 mcg/mL and 31.4 ± 5.6 mcg/mL, respectively, after a 1,500 mg/m2 nelarabine dose infused over 2 hours in adult patients. The area under the concentration-time curve (AUC) of ara-G is 37 times higher than that for nelarabine on Day 1 after nelarabine IV infusion of 1,500 mg/m2 dose (162 ± 49 mcg.h/mL versus 4.4 ± 2.2 mcg.h/mL, respectively). Comparable Cmax and AUC values were obtained for nelarabine between Days 1 and 5 at the nelarabine adult dosage of 1,500 mg/m2, indicating that nelarabine does not accumulate after multiple dosing. There are not enough ara-G data to make a comparison between Day 1 and Day 5. After a nelarabine adult dose of 1,500 mg/m2, intracellular Cmax for ara-GTP appeared within 3 to 25 hours on Day 1. Exposure (AUC) to intracellular ara-GTP was 532 times higher than that for nelarabine and 14 times higher than that for ara-G (2,339 ± 2,628 mcg.h/mL versus 4.4 ± 2.2 mcg.h/mL and 162 ± 49 mcg.h/mL, respectively).

Nelarabine and ara-G are partially eliminated by the kidneys. Mean urinary excretion of nelarabine and ara-G was 6.6 ± 4.7% and 27 ± 15% of the administered dose, respectively, in 28 adult patients over the 24 hours after nelarabine infusion on Day 1.

Nelarabine and ara-G are extensively distributed throughout the body. For nelarabine, V<sub>ss</sub> values were 197 ± 216 L/m<sup>2</sup> in adult patients. For ara-G, V<sub>ss</sub>/F values were 50 ± 24 L/m<sup>2</sup> in adult patients.

Renal clearance averaged 24 ± 23 L/h for nelarabine and 6.2 ± 5.0 L/h for ara-G in 21 adult patients. Combined Phase I pharmacokinetic data at nelarabine doses of 199 to 2,900 mg/m<sup>2</sup> (n = 66 adult patients) indicate that the mean clearance (CL) of nelarabine is 197 ± 189 L/h/m<sup>2</sup> on Day 1. The apparent clearance of ara-G (CL/F) is 10.5 ± 4.5 L/h/m<sup>2</sup> on Day 1. For pediatric patients receiving at a dose of 104 to 2,900 mg/m<sup>2</sup>, the combined Phase I pharmacokinetic data indicate that the mean clearance (CL) of nelarabine is 259 ± 409 L/h/m<sup>2</sup>, 30% higher than in adult patients. The apparent clearance of ara-G on day 1 is also higher in pediatric patients than in adult patients, estimated to be 11.3 ± 4.2 L/h/m<sup>2</sup>.

Cellular LocationsCytoplasm
応用分野 · 3 件

用途DNA 合成阻害作用を示します。

説明Nelarabine is a new member of the purine nucleoside antimetabolite class of drugs. It was launched as an intravenous infusion for treating relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) after at least two prior chemotherapy regimens. Nelarabine is a pro-drug of 9-b-D-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative with a high level of T-cell selective cytotoxicity. Although Ara-G has been known since the 1960s, it has not been used in clinical studies due to its poor solubility. Nelarabine is the O-methyl derivative of ara-G with approximately 10 times greater aqueous solubility. It is demethylated in vivo by adenosine deaminase to produce ara-G, which is subsequently converted to the active 5’-triphosphate, ara-GTP. Accumulation of ara-GTP in leukemic blasts allows for incorporation into DNA, leading to inhibition of DNA synthesis and cell death.

使用A chemotherapy drug used in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

補足説明 · 1 件

定義ChEBI: Nelarabine is a purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G). It has a role as an antineoplastic agent, a DNA synthesis inhibitor and a prodrug. It is a purine nucleoside, a beta-D-arabinoside and a monosaccharide derivative. It is functionally related to a guanine and a 9-beta-D-arabinofuranosylguanine.